Imbria Pharmaceuticals’ Post

Strong clinical evidence demonstrates that sustained LDL-C reductions improve cardiovascular outcomes. Lerodalcibep, our once-monthly, PCSK-9 lipid lowering therapy, has been observed in clinical trials to lower LDL-C levels by 59-77% on top of statins. www.libtherapeutics.com Join us at American College of Cardiology Scientific Session 2024 in Atlanta, GA where we will share topline data from one of our key Phase 3 studies of Lerodalcibep efficacy and safety in patients at very high or high risk for CVD on top of statins. #lerodalcibep #ACC2024 #PCSK9

https://lnkd.in/guh6mZgG Article title: Pregabalin overdose causing sinus bradycardia – A rare complication Author(s): Rajesh Kumar*; Jathinder Kumar; Ihtisham Malik; Gordon Pate Journal: Journal of Cardiovascular Medicine and Cardiology Journal ISSN: 2455-2976 Abstract: We present the unique case of severe, symptomatic bradycardia associated with pregabalin overdose. Pregabalin is a widely prescribed drug not routinely associated with sinus bradycardia. A 39 year old male, presented having taken about 4g of pregablin with intention to self-harm. Following admission, he subsequently developed bradycardia on telemetry. Other possible causes were excluded with serial investigations. The bradycardia resolved by 96 hours without the need for temporary pacing. Patients presenting with pregabalin overdose should be monitored for bradycardia. #Bradycardia #Overdose #Pregabalin #CoronaryArteryDiseases #ValvularHeartDisease #Electrophysiology #CardiacElectrophysiology #Echocardiography #InterventionalCardiology #ClinicalCardiology #NuclearCardiology #AcuteCoronarySyndromes #ArrhythmiaEP #CVImaging #CVDPrevention #CardiacArrhythmias #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #CardiacPhysiology #CardiacRegeneration #CardiacRehabilitation #Cardiomyopathies #CardiovascularDrugs #CardiovascularTherapy #CardiovascularAnatomy #CongenitalHeartDefects 

https://lnkd.in/gvnhZrte Article title: ACEi to ARNi: “The Switch” An Evidence Based Review Author(s): Yusuf Hassan*; Zahra Hassan; Ayesha Hassan; Asad A Saleem; Waqas Ahmed Journal: Journal of Cardiovascular Medicine and Cardiology Journal ISSN: 2455-2976 Abstract: Heart failure affects approximately 6.5 million adults in the United States, and the cost to healthcare system is tremendous [1]. Effective treatment for this very important disease is constantly evolving. The most significant change in the recent past has been the development of ARNI (Sacubitril/ Valsartan) for treatment of heart failure [2]. Recently ACC, AHA and HFSA, have recommended switching NYHA class II or class III patients to ARNI from ACE-I or ARB if they are symptomatic, (Class I recommendation) giving it level of evidence B-R. (Moderate quality evidence from 1 or more RCTs, or Moderate quality meta-analysis) [3]. #CoronaryArteryDiseases #ValvularHeartDisease #Electrophysiology #CardiacElectrophysiology #Echocardiography #InterventionalCardiology #ClinicalCardiology #NuclearCardiology #AcuteCoronarySyndromes #ArrhythmiaEP #CVImaging #CVDPrevention #CardiacArrhythmias #Peertechz #PeertechzPublications #OpenAccess #ScientificJournals #PeerReviewedJournals #OpenAccessPublishers #CardiacPhysiology #CardiacRegeneration #CardiacRehabilitation #Cardiomyopathies #CardiovascularDrugs #CardiovascularTherapy #CardiovascularAnatomy #CongenitalHeartDefects 

The use of a liberal transfusion strategy may be particularly impactful in type 1 #MI patients with anemia, according to a prespecified subgroup analysis of data from the MINT trial that reports a trend toward better outcomes. Read more on #CRTonline. #ACC24. https://lnkd.in/eSBQ_JVe #cardiacnurse #cardiologists #cardiology #cardiologyfellow #cardiologyfellows #cardiologynurse #cardiologynurses #cathlab #cathlabnurse #cathlabtech #interventionalcardiologists #interventionalcardiology #interventionalcardiologyfellow #interventionalcardiologyfellows #MCRN #medicalequity

Today, at the European Society of Cardiology Congress, Global Heart Hub will present a poster from their study: Insights from the Patients living with Elevated Cholesterol (IPEC). It is the patient perspective being presented by patients to physicians about the importance of decision-making when patients are first diagnosed with hypercholesterolemia. Delighted to see the patient voice present at medical congresses with such relevance! #patientengagement #patientvoice #patientdata #globalhearthub #ipec

Study Suggests AFib Prevalence in the USA Could Be Higher Than Expected A recent study published in the Journal of the American College of Cardiology suggests that over 10.5 million Americans may have Atrial Fibrillation (AFib) by today—a higher estimate than previously projected. https://lnkd.in/e9NrgqvD As the most common arrhythmia, AFib increases the risk of stroke and heart failure, making early detection critical. In recognition of AFib Awareness Month, AccurKardia is contributing with AccurECG™, our FDA-cleared, device agnostic software for automated ECG interpretation. AccurECG enables faster, more accurate arrhythmia detection, improving patient care and outcomes. Learn more about our mission by watching our corporate video: https://lnkd.in/ePNDwEtf #AFibAwareness #AccurECG #CardiacCare #ECG #BetterOutcomes

Woohoo! Our study reports the practice pattern of rate control in AFib. It may be the first report from a national cohort out of a general population in the US.#HealthServiceResearch #cardiohealth #cardiocare #AFib #PrimaryCare #HealthAnalytics #RWE #datadriven #slucare #slusom

Take a minute to learn about atrial fibrillation and rate control medications 👇 🎉 Kudos to the authors on this recent pub! Frick, W., Zidong Zhang, PhD, MPH, MS, Z., Rogers, L., Rojulpote, C. and Lin, C.J., 2024. Practice Patterns of Rate Control In Atrial Fibrillation and Clinical Outcomes From A Nationwide Cohort. Current Problems in Cardiology, p.102669. https://lnkd.in/gZZe4VHq

IAS is a global scientific partner in #INTERASPIRE, a groundbreaking study of more than 4,500 patients from 14 countries in all six WHO regions, due in part to support from Amarin Corporation. Results from the study were recently published in the European Heart Journal revealing major gaps in preventive care for coronary heart disease patients. It’s the first of many papers using INTERASPIRE data that will underscore the need for ongoing collaboration to reduce the global burden of #CHD. Look for more to come from IAS and the project's other partners: World Heart Federation, European Society of Cardiology, Inter-American Society of Cardiology, Pan-African Society of Cardiology, and the Asian Pacific Society of Cardiology. Learn more about INTERASPIRE ▶️ https://bit.ly/3TziuJs

Today, medical practice is changing rapidly, and the discipline of interventional cardiology is undergoing drastic changes every year. These changes directly affect patient care and require specific changes in the doctor's practice. The main goal of the series "Cardiovascular Interventions" is to provide the practitioner and the team for the treatment of cardiovascular diseases with a concentrated view of the latest developments in interventional cardiology in order to positively influence the results of patient treatment through real cases, expert lectures and discussion groups.